Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback